MIND Prize supports early-to-mid-career investigators pursuing bold basic and translational brain research to improve the prediction, prevention, and treatment of neurodegenerative diseases.
Funder: Pershing Square Philanthropies
Due Dates (Anticipated): September 2027 (LOI deadline)
Funding Amounts: $750,000 over three years ($250,000 annually)
Summary: Supports early-to-mid-career investigators pursuing bold, hypothesis-driven research to advance understanding of the brain and combat neurodegenerative diseases.
Key Information: Applicants must have 1–8 years of independent research experience by the prize start and work at a U.S. nonprofit research institution or equivalent.
The MIND (Maximizing Innovation in Neuroscience Discovery) Prize is part of the Pershing Square Foundation’s brain initiative. It supports early-to-mid-career investigators pursuing high-risk, high-reward basic and translational research to improve the prediction, prevention, and treatment of neurodegenerative diseases, including Alzheimer’s disease and dementia. The program seeks scientifically sound, radically innovative projects that may be too risky or speculative for traditional funding.
Research may span neurobiology, brain imaging and mapping, machine learning, drug delivery, synthetic biology, and other approaches to understanding brain biology and disease mechanisms. Projects can develop novel tools or explore approaches with extraordinary therapeutic potential, but must be grounded in a compelling biological question. The prize also fosters interdisciplinary collaboration across departments and institutions.